Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis
Public ClinicalTrials.gov record NCT03727802. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
TRK-250 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Inhaled Dose, Safety, Tolerability, and Pharmacokinetic Study of TRK-250 in Subjects With Idiopathic Pulmonary Fibrosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, at the gene expression level. This study is a double-blind, randomized, placebo-controlled Phase I study. The primary objective of the study is to assess the safety and tolerability of single and multiple inhaled doses of TRK-250 in subjects with idiopathic pulmonary fibrosis (IPF).
Study identification
- NCT ID
- NCT03727802
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 27, 2018
- Primary completion
- Mar 31, 2022
- Completion
- Mar 31, 2022
- Last update posted
- Oct 22, 2023
2018 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pulmonary Associates | Phoenix | Arizona | 85006 | — |
| Cedars-Sinai Medical Center (CSMC) - Women's Guild Lung Institute | Los Angeles | California | 90048 | — |
| UC Davis Medical Center | Sacramento | California | 95817 | — |
| Advanced Pulmonary & Sleep Research Institute of Florida | Daytona Beach | Florida | 32117 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Pulmonary Disease Specialists, PA, d/b/a PDS Research. Kissimmee, FL | Kissimmee | Florida | 34741 | — |
| Weill Cornell Medicine | New York | New York | 10021 | — |
| PulmonIx LLC | Greensboro | North Carolina | 27403 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Medical University of South Carolina - Pulmonary & Critical Care Clinical Research Program | Charleston | South Carolina | 29425 | — |
| The University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03727802, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2023 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03727802 live on ClinicalTrials.gov.